# A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

> **NCT03928743** · PHASE3 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 332 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Bimekizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03928743
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-25
- **Primary completion:** 2021-09-03
- **Final completion:** 2022-08-08
- **Target enrollment:** 332 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03928743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03928743, "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03928743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*